NYSE · Healthcare
Merck & Co., Inc. (MRK)
As-reported financials and recent SEC filings for Merck & Co., Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$65.01B
Net income
$18.25B
Net margin
28.1%
Diluted EPS
$7.28
ROE
34.7%
P/E (TTM)
33.5×
Market cap
$294.03B
Debt / equity
0.9×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $65.01B | $64.17B | $60.12B | $59.28B | $48.70B |
| Gross profit | $48.63B | $48.98B | $43.99B | $41.87B | $35.08B |
| Operating income | — | — | — | — | — |
| Net income | $18.25B | $17.12B | $365.0M | $14.52B | $13.05B |
| Diluted EPS | $7.28 | $6.74 | $0.14 | $5.71 | $5.14 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →42026-06-02
View on EDGAR →Go deeper on MRK
Search Merck & Co., Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.